GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operatio...(support provided by the HVTN. Dr. Mc...)

Dr. McNally concluded, "We believe we are well-positioned for success in 2009 and beyond, with our preventative vaccine beginning Phase 2 human testing and our therapeutic vaccine trial in the planning stage. Based on highly promising results in preclinical non-human primate studies conducted by Dr. Rama Amara at Emory University, we are eager to launch a therapeutic Phase 1/2 human clinical trial in individuals already infected with HIV to investigate the use of our vaccine as a therapeutic treatment to control HIV-virus levels. We expect this trial may start in mid-2009 and we will report on the development of this program as we conclude plans with our trial sponsor."

GEOVAX LABS, INC.

Condensed Consolidated Statements of Operations Information

(amounts in thousands, except per share data)

(unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

Revenues:

Grant Revenue $1,322 $- $2,298 $-

Operating expenses:

Research and

development 1,362 360 2,725 1,273

General and

administrative 699 815 2,322 1,865

2,061 1,175 5,047 3,138

Other income:

Interest income 17 9 60 52

17 9 60 52

Net loss $(722) $(1,166) $(2,689) $(3,086)

Loss per common share $(0.00) $(0.00) $(0.00) $(0.00)

GEOVAX LABS, INC.

Con
'/>"/>